Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
Details : EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds...
Brand Name : EscharEx
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 11, 2023
LOOKING FOR A SUPPLIER?
Reset All
